Definium Therapeutics posts narrower Q3 loss, reports Phase 3 wins and FDA breakthrough designations for DT120
Definium Therapeutics announced third‑quarter 2026 results showing a net loss of about $51 million, an improvement from the $67 million loss a year earlier. The company disclosed positive topline data from two Phase 3 anxiety studies and received FDA Breakthrough Therapy Designation for DT120 in major depressive disorder. It reaffirmed its plan to file a New Drug Application for DT120 in the first half of 2027 and said its cash balance of roughly $1.05 billion will fund operations into 2030.
Why it matters
The narrowed loss and strong cash position extend the company’s runway, reducing near‑term financing risk for investors. The FDA designations and Phase 3 results move DT120 closer to market, potentially enhancing the company’s valuation if the NDA is approved as scheduled.
Key facts
- 1Net loss for Q3 2026 was $51.0 million, compared with $67.3 million in the year‑ago quarter. tradingview.com
- 2Cash, cash equivalents and investments were approximately $1.05 billion at September 30 2026. tradingview.com
- 3Research and development expenses were $46.1 million in the quarter. tradingview.com
- 4Operating loss was $72.3 million for the quarter. tradingview.com
- 5DT120 met primary and all key secondary endpoints in the Phase 3 Voyage (214 participants) and Panorama (245 participants) GAD studies. finance.yahoo.com
- 6The FDA granted Breakthrough Therapy Designation to DT120 for major depressive disorder following the Phase 3 EMERGE study. finance.yahoo.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.